Integra LifeSciences (IART) Expected to Announce Quarterly Earnings on Tuesday

Integra LifeSciences (NASDAQ:IART) is projected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Integra LifeSciences to post earnings of $0.86 per share and revenue of $445.15 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $21.13 on Monday. The company’s fifty day moving average price is $23.71 and its 200-day moving average price is $21.81. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -234.75, a PEG ratio of 0.73 and a beta of 1.17. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.11. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Analysts Set New Price Targets

A number of brokerages have recently commented on IART. Morgan Stanley began coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target on the stock. Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.10% of the stock is owned by insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.